Patents by Inventor Nigel Stephen Watson

Nigel Stephen Watson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Crystalline derivatives of (E)-2-(5-chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide
    Patent number: 7645338
    Abstract: The present invention includes (E)-2-(5-Chlorothien-2-yl)-N-{(3S)-1-[(1S)-1-methyl-2-morpholin-4-yl-2-oxoethyl]-2-oxopyrrolidin-3-yl}ethenesulfonamide in substantially crystalline form, pharmaceutical formulations thereof, processes for preparing it, and its use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.
    Type: Grant
    Filed: December 4, 2003
    Date of Patent: January 12, 2010
    Assignee: Glaxo Group Limited
    Inventors: Philip C. Dell 'Orco, Henry Anderson Kelly, Gita Punjabhai Shah, Nigel Stephen Watson, Robert John Young
  • 3-Sulfonylamino-Pyrrolidine-2-One Derivatives as Factor Xa Inhibitors
    Publication number: 20090099231
    Abstract: The present invention provides pyrrolidinone derivatives as Factor Xa inhibitors and pharmaceutical compositions comprising the same. The invention also relates to processes for the preparation of such compounds, and the use of such compounds in medicine, particularly in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.
    Type: Application
    Filed: April 7, 2006
    Publication date: April 16, 2009
    Inventors: John David Harling, Nigel Stephen Watson, Robert John Young
  • Pyrrolidine derivatives as factor Xa inhibitors
    Patent number: 7517879
    Abstract: The invention relates to compounds of formula (I) processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.
    Type: Grant
    Filed: October 11, 2006
    Date of Patent: April 14, 2009
    Assignee: Glaxo Group Limited
    Inventors: Chuen Chan, Julie Nicole Hamblin, Henry Anderson Kelly, Nigel Paul King, Andrew McMurtrie Mason, Vipulkumar Kantibhai Patel, Stefan Senger, Gita Punjabhai Shah, Nigel Stephen Watson, Helen Elisabeth Weston, Caroline Whitworth, Robert John Young
  • Pyrrolidine-2-ones as Factor Xa inhibitors
    Patent number: 7482374
    Abstract: The invention relates to compounds of formula (I): wherein substituents are as defined.
    Type: Grant
    Filed: July 17, 2004
    Date of Patent: January 27, 2009
    Assignee: Glaxo Group Limited
    Inventors: Alan David Borthwick, Henry Anderson Kelly, Nigel Stephen Watson, Robert John Young
  • 1-Benzazepine-3-Sulfonylamino-2-Pyrroridones as Factor Xa Inhibitors
    Publication number: 20080306045
    Abstract: The invention relates to chemical entities of formula (I): and/or pharmaceutically acceptable derivative(s) thereof. The invention also relates to processes for the preparation of compounds of formula (I), pharmaceutical compositions containing compounds of formula (I) and to the use of compounds of formula (I) in medicine, particularly in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.
    Type: Application
    Filed: November 22, 2006
    Publication date: December 11, 2008
    Inventors: Laure Camus, Reshma Chudasama, Caroline Jane Day, Deepali Deshmukh, John Gerald Gleason, John David Harling, Chao-Pin Lee, Paula Saklatvala, Stefan Senger, Sarah Vallance, John Watson, Nigel Stephen Watson, Robert John Young, Barbara Yuan
  • Pyrrolidine derivatives as factor Xa inhibitors
    Patent number: 7429587
    Abstract: The invention relates to compounds of formula (I) processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.
    Type: Grant
    Filed: October 11, 2006
    Date of Patent: September 30, 2008
    Assignee: Glaxo Group Limited
    Inventors: Chuen Chan, Julie Nicole Hamblin, Henry Anderson Kelly, Nigel Paul King, Andrew McMurtrie Mason, Vipulkumar Kantibhai Patel, Stefan Senger, Gita Punjabhai Shah, Nigel Stephen Watson, Helen Elisabeth Weston, Caroline Whitworth, Robert John Young
  • 1-Phenyl-2-oxo-3-sulfonylamino-pyrrolidine derivatives and related compounds as factor Xa inhibitors for the treatment of acute vascular diseases
    Patent number: 7329685
    Abstract: The invention relates to compounds of formula (I): wherein substituents are as defined.
    Type: Grant
    Filed: June 17, 2004
    Date of Patent: February 12, 2008
    Assignee: Glaxo Group Limited
    Inventors: Alan David Borthwick, Chuen Chan, Henry Anderson Kelly, Savvas Kleanthous, Andrew McMurtrie Mason, Nigel Stephen Watson
  • Pyrrolidine derivatives as factor XA inhibitors
    Patent number: 7326785
    Abstract: The invention relates to compounds of formula (I) processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.
    Type: Grant
    Filed: October 11, 2006
    Date of Patent: February 5, 2008
    Assignee: Glaxo Group Limited
    Inventors: Chuen Chan, Julie Nicole Hamblin, Henry Anderson Kelly, Nigel Paul King, Andrew McMurtrie Mason, Vipulkumar Kantibhai Patel, Stefan Senger, Gita Punjabhai Shah, Nigel Stephen Watson, Helen Elisabeth Weston, Caroline Whitworth, Robert John Young
  • Pyrrolidin-2-one derivatives as inhibitors of factor xa
    Patent number: 7282497
    Abstract: The invention relates to compounds of formula (Ic) processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.
    Type: Grant
    Filed: March 17, 2006
    Date of Patent: October 16, 2007
    Assignee: Glaxo Group Limited
    Inventors: Chuen Chan, Julie Nicole Hamblin, Henry Anderson Kelly, Nigel Paul King, Andrew McMurtrie Mason, Vipulkumar Kantibhai Patel, Stefan Senger, Gita Punjabhai Shah, Nigel Stephen Watson, Helen Elisabeth Weston, Caroline Whitworth, Robert John Young
  • 3-sulfonylamino-pyrrolidine-2-one derivatives as inhibitors of factor Xa
    Patent number: 7235544
    Abstract: The invention relates to compounds of formula (I): wherein substituents are as defined.
    Type: Grant
    Filed: June 17, 2004
    Date of Patent: June 26, 2007
    Assignee: Glaxo Group Limited
    Inventors: Alan David Borthwick, John David Harling, Wendy Rebecca Irving, Savvas Kleanthous, Nigel Stephen Watson, Robert John Young
  • Pyrrolidin-2-one derivatives as inhibitors of factor xa
    Patent number: 7226929
    Abstract: The invention relates to compounds of formula (Ic) processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.
    Type: Grant
    Filed: March 17, 2006
    Date of Patent: June 5, 2007
    Assignee: SmithKline Beecham Corporation
    Inventors: Chuen Chan, Julie Nicole Hamblin, Henry Anderson Kelly, Nigel Paul King, Andrew McMurtrie Mason, Vipulkumar Kantibhai Patel, Stefan Senger, Gita Punjabhai Shah, Nigel Stephen Watson, Helen Elisabeth Weston, Caroline Whitworth, Robert John Young
  • Pyrrolidine derivatives as Factor Xa inhibitors
    Patent number: 7186717
    Abstract: The invention relates to compounds of formula (I) processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.
    Type: Grant
    Filed: June 6, 2002
    Date of Patent: March 6, 2007
    Assignee: SmithKline Beecham Corporation
    Inventors: Chuen Chan, Julie Nicole Hamblin, Henry Anderson Kelly, Nigel Paul King, Andrew McMurtrie Mason, Vipulkumar Kantibhai Patel, Stefan Senger, Gita Punjabhai Shah, Nigel Stephen Watson, Helen Elisabeth Weston, Caroline Whitworth, Robert John Young
  • 2-(3-sulfonylamino-2-oxopyrrolidin-1-yl)propanamides as factor xa inhibitors
    Patent number: 7179835
    Abstract: The invention relates to compounds of formula (I) pharmaceutical compositions containing the same as well as methods of treating patients suffering from a condition susceptible to amelioration by a Factor Xa inhibitor using the same.
    Type: Grant
    Filed: November 13, 2002
    Date of Patent: February 20, 2007
    Assignee: Glaxo Group Limited
    Inventors: Alan David Borthwick, Matthew Campbell, Chuen Chan, Henry Anderson Kelly, Nigel Paul King, Savvas Kleanthous, Andrew McMurtrie Mason, Stefan Senger, Paul William Smith, Nigel Stephen Watson, Robert John Young
  • Pyrrolidin-2-one derivatives as inhibitors of factor Xa
    Patent number: 7084139
    Abstract: The invention relates to compounds of formula (Ic) processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.
    Type: Grant
    Filed: June 6, 2002
    Date of Patent: August 1, 2006
    Assignee: SmithKline Beecham Corporation
    Inventors: Chuen Chan, Julie Nicole Hamblin, Henry Anderson Kelly, Nigel Paul King, Andrew McMurtrie Mason, Vipulkumar Kantibhai Patel, Stefan Senger, Gita Punjabhai Shah, Nigel Stephen Watson, Helen Elisabeth Weston, Caroline Whitworth, Robert John Young
  • Pyrrolidin-2-one derivatives as inhibitors of factor xa
    Publication number: 20040152697
    Abstract: The invention relates to compounds of formula (Ic) processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.
    Type: Application
    Filed: December 3, 2003
    Publication date: August 5, 2004
    Inventors: Chuen Chan, Julie Nicole Hamblin, Henry Anderson Kelly, Nigel Paul King, Andrew McMurtrie Mason, Vipulkumar Kantibhai Patel, Stefan Senger, Gita Punjabhai Shah, Nigel Stephen Watson, Helen Elisabeth Weston, Caroline Whitworth, Robert John Young
  • Benzamide derivatives as thrombin inhibitors
    Patent number: 6326386
    Abstract: The invention relates to a novel class of amide derivatives which act as thrombin inhibitors as described by formula (I), where R1 and R2, independently represent a group (a) or R1 and R2 together form a C3-7 heterocycloalkyl or heterocycloalkenyl group which may be optionally substituted by C1-6 alkyl, C1-4 alkoxy, halogen, carboxylic acid or a C1-4 carboxylic acid ester group; R3 represents hydrogen, C1-3 alkyl, halogen, or C1-2 alkoxy; R4, R5 and R6 independently represent hydrogen, or halogen; R7 represents hydrogen or C1-6 alkyl; R8 represents hydrogen, C3-7 cycloalkyl, C3-7 cycloalkenyl, C3-7 heterocycloalkyl, C3-7 heterocycloalkenyl, aryl or heteroaryl, which groups are optionally substituted by one or more groups selected from halogen, hydroxy, CN, C1-6 alkyl, C1-6 alkoxy, C1-6 acyloxy, NR9R10, NHCOR11, NHSO2R12, COR13, CO2R14, CONR15R16, and SO2NHR17; X represents a bond, a C1-6 alkyl chain, or a C3-6 alkenyl chain, where one or two nitrogen, oxygen, or sulfur atoms may be optionally contained within
    Type: Grant
    Filed: October 4, 2000
    Date of Patent: December 4, 2001
    Assignee: Glaxo Group Limited
    Inventors: Nigel Stephen Watson, Martin Pass, Vipulkumar Patel